S&P 500 7,623.68 −0.52%
Nasdaq 25,955.34 −0.21%
S&P/TSX 35,788.18 −0.52%
Apple 347.73 −0.14%
Nvidia 210.96 −0.59%
Microsoft 524.51 +0.66%
Shopify 236.24 −0.07%
Royal Bank 281.77 −0.36%
CAD/USD 0.7141 −0.01%
CLOSED · 08:50 ET
Market ClerkRecap
Sun Oct 25 · markets closed1 signal on Oct 2494 insider buys this week · $48.3MCIRO short report next: Oct 31The week ahead

CERS

CERUS CORP
NASDAQ · HEALTH CARE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
2.33
+0.02 +0.87%
USD · close Oct 23
WatchTime Machine

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $469.6MP/E —DIV YIELD —FCF YIELD -0.39%REV TTM —NET INCOME −$6.8MNET DEBT $2M52W 1.40 – 3.28SEC XBRL · TTM TO Invalid Date

How CERS rewrote its risk factors

10-K ITEM 1A · FY2024 → FY2025
Text kept
66%
of sentences unchanged
Added
328
new sentences
Dropped
334
sentences removed
Length
−89
words, now 60,820

New in FY2025

  • As a result, we may not be able to successfully educate the market on the value of pathogen reduction or commercialize our products. • An inability to successfully transition from a direct selling model to a kit model, as well as an inability to successfully commercialize the INTERCEPT Blood System for Cryoprecipitation in the U.S. would have a material adverse effect on our business, financial condition, results of operations and growth prospects. • If our competitors develop products superior to ours, market their products more effectively, or receive regulatory approval or certification before our products, our commercial opportunities could be reduced or be eliminated.
  • Food and Drug Administration’s, or FDA’s, or other regulatory authorities’ good manufacturing practice regulations, it could impair our ability to market our products in a cost-effective and timely manner. • If we modify our FDA-approved or CE Marked products, we may need to seek additional approvals or certification, which, if not granted, would prevent us from selling our modified products. • We are subject to federal, state and foreign laws governing our business practices which, if violated, could result in substantial penalties and harm our reputation and business. • A significant portion of the funding for the development of the red blood cell system has come and is expected to continue to come from our BARDA agreements, and if BARDA were to eliminate, reduce or delay, or object to additional activities or extensions for funding of our agreements, it would have a significant, negative impact on our government contract revenues and cash flows, and we may be forced to suspend or terminate our U.S. red blood cell development program or obtain alternative sources of funding.
  • Our ability to be paid by the DoD is predicated on our ability to achieve the stated milestones in the agreement and for the DoD to agree with the successful completion of each. • We rely on third parties to market, sell, distribute and maintain our products and to maintain customer relationships in certain countries. • Our manufacturing supply chain exposes us to significant risks. • We may continue to generate losses and never achieve a profitable level of operations. • We may not be able to achieve, or sustain, profitability. • If we fail to obtain the capital necessary to fund our future operations or if we are unable to generate continued positive cash flows from our operations, we will need to curtail planned development or sales and commercialization activities. • We operate a complex global commercial organization, with limited experience in many countries.
  • We may be distracted by expansion into new geographies where we do not have experience and we may be unsuccessful in monetizing such opportunities for the benefit of our organization at large. • Adverse market and economic conditions as well as tariffs and escalating international trade tensions may exacerbate certain risks affecting our business. • Risks associated with our operations outside of the United States could adversely affect our business. • We may not be able to protect our intellectual property or operate our business value. • Our stock price is volatile and your investment may suffer a decline in value.
  • The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals and certification, including but not limited to FDA approval in the U.S., CE Certificates of Conformity delivered in accordance with the Medical Devices Regulation 2017/745, or MDR, permitting us to affix the CE Mark to our products and place them on the market in the European Union and other jurisdictions that recognize the CE Mark, and are being marketed and sold in a number of countries around the world, including the U.S., certain countries in Europe, the Commonwealth of Independent States, or CIS, the Middle East, and Latin America and selected countries in other regions of the world.
  • We are currently conducting a Phase 3 clinical trial - the RedeS study, to assess the safety and efficacy of INTERCEPT-treated red blood cells when compared to conventional, un-treated, red blood cells.
  • With respect to our application for conformity assessment under the MDR to obtain a CE Certificate of Conformity and affix the CE Mark, or MDR application, in the European Union, or EU, we announced in October 2024 that the Dutch Medicines Evaluation Board, or CBG, the Competent Authority for the red blood cell system, reviewed the active pharmaceutical ingredient module of our MDR application and concluded that the data included in the module were insufficient to support the proposed classification of the impurity profile of the final product, necessitating the closure of our MDR application without successful completion of the conformity assessment or issuance of a CE Certificate of Conformity.
  • In collaboration with TÜV-SÜD, our Notified Body for the red blood cell system, we developed a plan for resubmission of our application and identified a new Competent Authority.
  • We revised our MDR application to address the questions raised by CBG and submitted a new MDR application for the red blood cell system to TÜV-SÜD.
  • In July 2025, we announced that TÜV-SÜD completed their clinical assessment of our new MDR application and transferred information regarding the active substances, or API, to the identified competent authority, the State Institute for Drug Control, or SÚKL.
  • After discussions with TÜV-SÜD, we decided to transfer the review of the API from SÚKL to the French National Agency for Medicines and Health Products Safety, or ANSM.
  • We cannot predict if or when a decision concerning certification would occur.
  • In addition, as a result of the failure to obtain a CE Certificate of Conformity following MDR application, our product development costs will be ongoing.
  • In order to successfully commercialize all of our products and product candidates, we will be required to conduct significant research, development, preclinical and clinical evaluation, commercialization and regulatory compliance activities for our products and product candidates, which, together with selling, general and administrative expenses, may result in operating losses.
  • While our goal is to achieve and maintain a profitable level of operations, we may be unable to do so.
  • Products, Product Candidates and Development Activities The following table identifies our products, product candidates and product development activities and their current status: Product or Product Candidate Under Development Product or Development Status INTERCEPT Blood System—Platelets • Commercialized in the U.S., Canada and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world • Received CE Certificate of Conformity and CE Marked under MDR in 2023 INTERCEPT Blood System—Plasma • Commercialized in the U.S. and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world • Received CE Certificate of Conformity and CE Marked under MDR in 2023 • Received FDA approval of the premarket approval supplement, or PMA, to produce IFC in 2020 INTERCEPT Blood System—Red Blood Cells • U.S.
  • Phase 3 clinical trial, known as the RedeS study, completed enrollment in 2025 • U.S.
  • Phase 3 acute anemia clinical trial, known as the ReCePI study, completed in 2024 • Additional U.S. studies also planned • European Phase 3 acute anemia clinical trial completed in 2014; European Phase 3 chronic anemia clinical trial completed in 2017 • Application for a conformity assessment to obtain a CE Certificate of Conformity and affix the CE Mark for the EEA was resubmitted in 2025 INTERCEPT Blood System—Cryoprecipitation • Received FDA approval of the premarket approval supplement with respect to IFC in 2020 • U.S. agreement with certain blood center manufacturing partners INTERCEPT Illuminator—LED-based • Commercialized in a number of countries in Europe and selected countries in other regions around the world • Received CE Certificate of Conformity and CE Marked under MDR in 2025 INTERCEPT Blood System for Platelets, Plasma and Cryoprecipitation The platelet system and plasma system are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion.
  • Both systems received a CE Certificate of Conformity in accordance with the MDR permitting us to affix the CE Mark in the European Economic Area, or EEA, and FDA approval in the U.S. and are currently marketed and sold in a number of countries around the world including the U.S., countries in Europe, the CIS, the Middle East and selected countries in other regions of the world.
  • We have received CE Certificates of Conformity to affix the CE Mark in accordance with the MDR for our INTERCEPT platelet and plasma systems which allows us to continue to place our platelet and plasma systems on the European Union market in accordance with the regulatory requirements of the MDR.
  • We expect our commercial efforts in 2026 will be focused on increasing market adoption of INTERCEPT products by enabling blood center customers to increase the number of platelet and plasma units produced and made available to patients.
  • For IFC, we are shifting our focus from selling finished therapeutic doses to hospitals to selling kits to blood centers.
  • We plan to continue to develop and raise awareness of INTERCEPT’s product profile relative to other products, including conventional, un-treated components.
  • To distribute blood products, including IFC, to hospitals through interstate commerce, U.S.-based blood centers will need to complete process validations and obtain site-specific licenses from the FDA Center for Biologics Evaluation and Research, or CBER, before those blood products can be made available to hospital customers outside of the state of IFC production.
  • In addition, the majority of platelets used in the U.S. are collected by apheresis, which is part of our FDA-approved label for the platelet system, though a significant minority are prepared from pooled random donor platelets derived from whole blood collections.
  • While available in Europe and other regions around the world, in order to gain FDA approval for a pathogen reduction system compatible with pooled random donor platelets, we will need to perform additional product development and testing, including additional clinical trials, and will need to obtain FDA approval of a PMA supplement.
  • We do not currently have plans to pursue this configuration.
  • We will also need to obtain new PMAs for our INTERCEPT platelet and plasma systems for use with our new LED-based illuminator.
  • We plan to submit our PMA application for our new LED-based illuminator in mid-2026.
  • We have since successfully completed European Phase 3 clinical trials of the red blood cell system for subjects with acute and chronic anemia patients to support an MDR application.
  • We initially filed an application for conformity assessment to obtain a CE Certificate of Conformity for the red blood cell system in December 2018 under the Medical Device Directive, or MDD, and in June 2021, we submitted an MDR application.
  • In October 2024, we announced that TÜV-SÜD, in consultation with CBG, reviewed information regarding the medicinal product or active pharmaceutical ingredient of our MDR application and concluded that the data provided were insufficient to support the proposed classification of the impurity profile of the final product, necessitating the closure of our MDR application without successful completion of the conformity assessment and issuance of a CE Certificate of Conformity.
  • In collaboration with TÜV-SÜD, we developed a plan for resubmission of our application and identified a new Competent Authority.
  • In July 2025, we announced that TÜV-SÜD completed their clinical assessment of our new MDR application and transferred information regarding the API to the identified competent authority, SÚKL.
  • After discussions with TÜV-SÜD, we decided to transfer the review of the API from SÚKL to ANSM.
  • In addition, as a result of the resubmission of our MDR application, our product development costs will be ongoing.
  • In the U.S., we are conducting the Phase 3 RedeS study, a double-blind, controlled, parallel group study randomized to receive either 28 days, or 28 days plus 6 months of transfusion support with INTERCEPT-treated RBCs or conventional RBCs (test or control with 1:1 ratio), with a primary endpoint of hemoglobin increment following transfusion.
  • The study completed enrollment during the fourth quarter of 2025 of 689 patients including 130 transfused patients for the 6-month chronic phase for subjects requiring simple repeat transfusions and 25 transfused patients with Sickle Cell Disease requiring red cell exchange.
  • Subjects that qualified for inclusion into the chronic phase were those with conditions such as Sickle Cell Disease, Thalassemia, or Myelodysplasia.
  • If treatment emergent antibody reactions associated with hemolysis are observed, the FDA will require us to place a clinical hold and we will need to investigate the underlying cause.

and 288 more.

Gone since FY2024

  • As a result, we may not be able to successfully educate the market on the value of pathogen reduction or commercialize our products. • We have very limited experience selling directly to hospitals or expertise complying with regulations governing finished biologics, and our inability to successfully commercialize the INTERCEPT Blood System for cryoprecipitation in the U.S. would have a material adverse effect on our business, financial condition, results of operations and growth prospects. • If our competitors develop products superior to ours, market their products more effectively, or receive regulatory approval or certification before our products, our commercial opportunities could be reduced or be eliminated.
  • Food and Drug Administration’s, or FDA’s, or other regulatory authorities’ good manufacturing practice regulations, it could impair our ability to market our products in a cost-effective and timely manner. • If we modify our FDA-approved or CE Marked products, we may need to seek additional approvals or certification, which, if not granted, would prevent us from selling our modified products. • We are subject to federal, state and foreign laws governing our business practices which, if violated, could result in substantial penalties and harm our reputation and business. • A significant portion of the funding for the development of the red blood cell system has come and is expected to continue to come from our BARDA agreements, and if BARDA were to eliminate, reduce or delay, or object to extensions for funding of our agreements, it would have a significant, negative impact on our government contract revenues and cash flows, and we may be forced to suspend or terminate our U.S. red blood cell development program or obtain alternative sources of funding.
  • Our ability to be paid by the DoD is predicated on our ability to achieve the stated milestones in the agreement and for the DoD to agree with the successful completion of each. • We rely on third parties to market, sell, distribute and maintain our products and to maintain customer relationships in certain countries. • Our manufacturing supply chain exposes us to significant risks. • We may continue to generate losses and never achieve a profitable level of operations. • If we fail to obtain the capital necessary to fund our future operations or if we are unable to generate continued positive cash flows from our operations, we will need to curtail planned development or sales and commercialization activities. • We operate a complex global commercial organization, with limited experience in many countries.
  • We may be distracted by expansion into new geographies where we do not have experience and we may be unsuccessful in monetizing such opportunities for the benefit of our organization at large. • Adverse market and economic conditions may exacerbate certain risks affecting our business. • Risks associated with our operations outside of the United States could adversely affect our business. • We may not be able to protect our intellectual property or operate our business without infringing intellectual property rights of others. • Our stock price is volatile and your investment may suffer a decline in value.
  • The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals and certification, including but not limited to FDA approval in the U.S., CE Certificates of Conformity delivered in accordance with the Medical Devices Directive 93/42/EEC, or MDD, and the Medical Devices Regulation 2017/745, or MDR, permitting us to affix the CE Mark to our products and place them on the market in the European Union and other jurisdictions that recognize the CE Mark, and are being marketed and sold in a number of countries around the world, including the U.S., certain countries in Europe, the Commonwealth of Independent States, or CIS, the Middle East, and Latin America and selected countries in other regions of the world.
  • The INTERCEPT Blood System for red blood cells, or the red blood cell system, is currently in development.
  • In the U.S., we are currently conducting a Phase 3 clinical trial - the RedeS study, to assess the safety and efficacy of INTERCEPT-treated red blood cells when compared to conventional, un-treated, red blood cells.
  • With respect to our MDR application in the European Union, or EU, we announced in October 2024 that the Dutch Medicines Evaluation Board, or CBG, the Competent Authority for the red blood cell system, reviewed the active pharmaceutical ingredient module of our MDR application and concluded that the data included in the module were insufficient to support the proposed classification of the impurity profile of the final product, necessitating the closure of our MDR application without an approval.
  • In collaboration with TÜV-SÜD, our Notified Body for the red blood cell system, we are assessing strategies for a potential new MDR application, including data to address the classification questions raised by CBG.
  • We cannot predict with certainty when, if ever, we will be able to satisfactorily address CBG’s conclusions and as such cannot predict if or when we will submit a new MDR application for the red blood cell system and, if submitted, when a decision concerning certification would occur.
  • In addition, as a result of the failure to obtain approval of our MDR application, our product development costs will be ongoing.
  • Contribution margins from our sales is likely to be less than the cost of our operating expenses.
  • In order to successfully commercialize all of our products and product candidates, we will be required to conduct significant research, development, preclinical and clinical evaluation, commercialization and regulatory compliance activities for our products and product candidates, which, together with anticipated increased selling, general and administrative expenses, are expected to result in substantial operating losses.
  • Products, Product Candidates and Development Activities The following table identifies our products, product candidates and product development activities and their current status: Product or Product Candidate Under Development Product or Development Status INTERCEPT Blood System—Platelets • Commercialized in the U.S., Canada and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world • Received CE Certificate of Conformity under MDR in December 2023 INTERCEPT Blood System—Plasma • Commercialized in the U.S. and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world • Received CE Certificate of Conformity under MDR in December 2023 • Received FDA approval of the premarket approval supplement, or PMA, to produce IFC in 2020 INTERCEPT Blood System—Red Blood Cells • U.S.
  • Phase 3 clinical trial, known as the RedeS study, enrolling patients • U.S.
  • Phase 3 acute anemia clinical trial, known as the ReCePI study, completed in 2024 • Additional U.S. studies also planned • European Phase 3 acute anemia clinical trial completed in 2014; European Phase 3 chronic anemia clinical trial completed in 2017 • Resubmission of application for CE Certificate of Conformity under MDR would be required in order to potentially obtain marketing approval in Europe INTERCEPT Blood System—Cryoprecipitation • FDA approval in November 2020 • U.S. agreement with certain blood center manufacturing partners • Limited commercialization in the U.S.
  • INTERCEPT Blood System for Platelets, Plasma and Cryoprecipitation The platelet system and plasma system are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion.
  • Both systems received a CE Certificate of Conformity permitting us to affix the CE Mark in the European Economic Area, or EEA, and FDA approval in the U.S. and are currently marketed and sold in a number of countries around the world including the U.S., countries in Europe, the CIS, the Middle East and selected countries in other regions of the world.
  • We have received CE Certificates of Conformity to affix the CE Mark in accordance with the MDR for our INTERCEPT platelet and plasma systems which allows us to continue to place our platelet and plasma systems on the European Union market under the new regulatory requirements of the MDR.
  • We expect our commercial efforts in 2025 will continue to largely be focused on enabling blood centers that are using INTERCEPT to increase the number of platelet and plasma units produced and made available to patients.
  • In addition, we plan to sell the INTERCEPT Blood System for Cryoprecipitation to certain blood center customers and to sell IFC to hospital customers.
  • In addition, we plan to continue to develop awareness of INTERCEPT’s product profile relative to other platelet and plasma products, including conventional, un-treated components.
  • To enable broader patient access to IFC in the U.S., U.S.-based blood centers need to complete process validations and obtain site-specific licenses from the FDA Center for Biologics Evaluation and Research, or CBER, before IFC can be made available to hospital customers outside of the state of IFC production.
  • We have contracted with several blood centers to produce IFC for us which we sell directly to hospitals and to other blood centers.
  • Of the blood centers that we have contracted with to produce IFC for us, all have received their interstate licenses, or BLAs.
  • Further, the hospital customers of blood centers may need to complete changes to their administrative processes of generating internal tracking codes to integrate INTERCEPT-treated products into their inventories prior to receiving INTERCEPT-treated components.
  • In addition, we estimate that the majority of platelets used in the U.S. are collected by apheresis, which is part of our FDA-approved label for the platelet system, though a significant minority are prepared from pooled random donor platelets derived from whole blood collections.
  • While available in Europe and other regions around the world, in order to gain FDA approval for a pathogen reduction system compatible with triple dose collections and random donor platelets, we will need to perform additional product development and testing, including additional clinical trials, and will need to obtain FDA approval of a PMA supplement.
  • We do not currently have plans to pursue these configurations.
  • We also understand that we will need to obtain new PMAs for our INTERCEPT platelet and plasma systems for use with our new LED-based illuminator.
  • We have since successfully completed European Phase 3 clinical trials of the red blood cell system for subjects with acute and chronic anemia patients to support an application for a CE Certificate of Conformity.
  • We initially filed an application for a CE Certificate of Conformity for the red blood cell system in December 2018 under the Medical Device Directive, or MDD, and in June 2021, we completed our application for a CE Certificate of Conformity under the new MDR.
  • In October 2024, we announced CBG, the Competent Authority for the red blood cell system, concluded that the data provided regarding the medicinal product or active pharmaceutical ingredient of our MDR application were insufficient to support the proposed classification of the impurity profile of the final product, necessitating the closure of our MDR application without an approval.
  • In collaboration with TÜV-SÜD, we are assessing strategies for a potential new MDR application, including data to address the classification questions raised by CBG.
  • In the U.S., we successfully completed a Phase 2 recovery and lifespan study of INTERCEPT-treated RBCs.
  • Subsequently, we initiated a double-blind Phase 3 clinical study, known as the RedeS study, to assess the safety and efficacy of INTERCEPT-treated RBCs when compared to conventional RBCs in regions impacted by the Zika virus epidemic.
  • The RedeS study was expanded to other areas at risk for transfusion-transmitted infections.
  • The FDA has agreed to modify the criteria for a clinical pause if we see three or more treatment emergent antibodies with amustaline specificity without evidence of hemolysis in patients receiving INTERCEPT-treated RBCs in our RedeS study.
  • We are now allowed to continue study enrollment for the RedeS study while we investigate the clinical significance of the antibodies.
  • If we determine that there is no clinical significance and no impact on patients, then there will be no impact on study enrollment.

and 294 more.

Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.

Watch CERS. Know when insiders buy.
One email the day a filing lands. Free.